The NeedleVue LC1 Ultrasound System is designed to provide sub-millimeter level guidance during interventional procedures.
DeepSight Technology has received 510(k) clearance from the US Food and Drug Administration (FDA) for its NeedleVue LC1 Ultrasound System. The system is intended to provide clinicians with improved visualization for image-guided procedures.
According to the company, the clearance is a key step in the development of its NeedleVue and OnPoint technologies, which will operate with the NeedleVue LC1 Ultrasound System. The technology aims to enhance procedural efficiency and user confidence by delivering high-resolution imaging.
“This is a foundational milestone in our mission to deliver crystal clear, sub-millimeter level guidance inside the body,” says Nader Sadrzadeh, CEO of DeepSight, in a release. “We have developed the next-generation sensor technology for enhancing ultrasound where it what matters most—clear visualization, procedural efficiency, and user confidence. We’re just getting started and look forward to building on this achievement as we expand our clinical and commercial momentum in the months ahead.”
DeepSight Technology was founded in 2019 and has offices in the San Francisco Bay Area and Clayton, Missouri. The company will be demonstrating the NeedleVue technology at the LSI’25 Europe meeting in London from Sept 7-11 and the Cardiovascular and Interventional Radiological Society of Europe conference in Barcelona from Sept 13-17.
Photo caption: NeedleVue LC1 Ultrasound System
Photo credit: DeepSight Technology
We Recommend for You:
